Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
نویسندگان
چکیده
منابع مشابه
Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
Ferric citrate hydrate was recently approved in Japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (CKD). The daily therapeutic dose is about 3 to 6 g, which comprises about 2 to 4 g of citrate. Oral citrate solubilizes aluminum that is present in food and drinking water, and opens the tight junctions in the intes...
متن کاملAdministration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
BACKGROUND/AIM Dietary phosphate intake and vitamin D receptor activator (VDRA) regulate fibroblast growth factor 23 (FGF23); iron may modulate FGF23 metabolism. We aimed to determine whether oral iron supplementation influences serum FGF23 concentration in hemodialysis (HD) patients, while excluding the effect of dietary phosphate intake. METHODS This prospective study enrolled 27 maintenanc...
متن کاملEfficacy of ferric citrate as a phosphate-binding agent in end-stage renal disease.
Sir, I read with great interest the article by Yang et al. w1x, describing the role of ferric citrate as a phosphate binder in haemodialysis patients. Dr Yang and colleagues have presented their data (Table 3), which demonstrate convincingly that ferric citrate lowers serum phosphate, though not as significantly as calcium carbonate. However, the presentation of statistically significant data c...
متن کاملNet Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
Ferric citrate (FC) has demonstrated efficacy as a phosphate binder and reduces the requirements for erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron in dialysis patients. We developed a net budgetary impact model to evaluate FC vs. other phosphate binders from the vantage of a large dialysis provider. We used a Markov microsimulation model to simulate mutually referential lon...
متن کاملComment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
In 2012, total treatment costs for end-stage renal disease (ESRD) [in-center dialysis and outpatient costs combined] were estimated to be about US$88,000 per person per year [1]. For payers, this represents over US$7000 per member per month (PMPM) in expenses, a substantial burden. Therefore, analyses of ESRD costs are vital. Brunelli et al. conducted a budget impact analysis of a new phosphate...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmaceuticals
سال: 2014
ISSN: 1424-8247
DOI: 10.3390/ph7100990